Camilla Krakstad

List of Publications by Year
in descending order

134	5,795	109321	88630
papers	citations	35 h-index	70 g-index

139	139	139	10865
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Preoperative pelvic MRI and 2-[18F]FDG PET/CT for lymph node staging and prognostication in endometrial cancerâ€"time to revisit current imaging guidelines?. European Radiology, 2023, 33, 221-232.	4.5	3
2	Longitudinal effects of adjuvant chemotherapy and lymph node staging on patient-reported outcomes in endometrial cancer survivors: a prospective cohort study. American Journal of Obstetrics and Gynecology, 2022, 226, 90.e1-90.e20.	1.3	9
3	MRI-assessed tumor-free distance to serosa predicts deep myometrial invasion and poor outcome in endometrial cancer. Insights Into Imaging, 2022, 13, 1.	3.4	14
4	Interobserver agreement and prognostic impact for MRIâ€"based 2018 FIGO staging parameters in uterine cervical cancer. European Radiology, 2022, 32, 6444-6455.	4.5	5
5	High-Grade Cervical Intraepithelial Neoplasia (CIN) Associates with Increased Proliferation and Attenuated Immune Signaling. International Journal of Molecular Sciences, 2022, 23, 373.	4.1	11
6	Fully Automatic Whole-Volume Tumor Segmentation in Cervical Cancer. Cancers, 2022, 14, 2372.	3.7	9
7	What MRI-based tumor size measurement is best for predicting long-term survival in uterine cervical cancer?. Insights Into Imaging, 2022, 13, .	3.4	8
8	Cancer awareness in the general population varies with sex, age and media coverage: A population-based survey with focus on gynecologic cancers. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2021, 256, 25-31.	1.1	4
9	Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer. International Journal of Cancer, 2021, 148, 307-319.	5.1	35
10	Wholeâ€Volume Tumor <scp>MRI</scp> Radiomics for Prognostic Modeling in Endometrial Cancer. Journal of Magnetic Resonance Imaging, 2021, 53, 928-937.	3.4	47
11	Maintained survival outcome after reducing lymphadenectomy rates and optimizing adjuvant treatment in endometrial cancer. Gynecologic Oncology, 2021, 160, 396-404.	1.4	11
12	The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study. Human Pathology, 2021, 109, 80-91.	2.0	22
13	Automated segmentation of endometrial cancer on MR images using deep learning. Scientific Reports, 2021, 11, 179.	3.3	24
14	Nuclear upregulation of class I phosphoinositide 3-kinase p110Î² correlates with high 47S rRNA levels in cancer cells. Journal of Cell Science, 2021, 134, .	2.0	7
15	An MRI-Based Radiomic Prognostic Index Predicts Poor Outcome and Specific Genetic Alterations in Endometrial Cancer. Journal of Clinical Medicine, 2021, 10, 538.	2.4	15
16	A 10-gene prognostic signature points to LIMCH1 and HLA-DQB1 as important players in aggressive cervical cancer disease. British Journal of Cancer, 2021, 124, 1690-1698.	6.4	15
17	Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer. American Journal of Obstetrics and Gynecology, 2021, 225, 407.e1-407.e16.	1.3	11
18	Incorporating molecular profiling into endometrial cancer management requires prospective studies. International Journal of Gynecological Cancer, 2021, 31, 944-945.	2.5	10

#	Article	IF	Citations
19	Genetic analyses of gynecological disease identify genetic relationships between uterine fibroids and endometrial cancer, and a novel endometrial cancer genetic risk region at the WNT4 1p36.12 locus. Human Genetics, 2021, 140, 1353-1365.	3.8	18
20	Patient-derived organoids reflect the genetic profile of endometrial tumors and predict patient prognosis. Communications Medicine, 2021, 1, .	4.2	20
21	Feasibility and utility of MRI and dynamic 18F-FDG-PET in an orthotopic organoid-based patient-derived mouse model of endometrial cancer. Journal of Translational Medicine, 2021, 19, 406.	4.4	5
22	Genomic Characterization and Therapeutic Targeting of HPV Undetected Cervical Carcinomas. Cancers, 2021, 13, 4551.	3.7	13
23	Genomic alterations associated with mutational signatures, DNA damage repair and chromatin remodeling pathways in cervical carcinoma. Npj Genomic Medicine, 2021, 6, 82.	3.8	9
24	A Gene Signature Identifying CIN3 Regression and Cervical Cancer Survival. Cancers, 2021, 13, 5737.	3.7	9
25	Risk Stratification of Endometrial Cancer Patients: FIGO Stage, Biomarkers and Molecular Classification. Cancers, 2021, 13, 5848.	3.7	40
26	A radiogenomics application for prognostic profiling of endometrial cancer. Communications Biology, 2021, 4, 1363.	4.4	14
27	Blood steroid levels predict survival in endometrial cancer and reflect tumor estrogen signaling. Gynecologic Oncology, 2020, 156, 400-406.	1.4	8
28	Preoperative risk stratification in endometrial cancer (ENDORISK) by a Bayesian network model: A development and validation study. PLoS Medicine, 2020, 17, e1003111.	8.4	25
29	Improving response to progestin treatment of low-grade endometrial cancer. International Journal of Gynecological Cancer, 2020, 30, 1811-1823.	2.5	21
30	Preoperative 18F-FDG PET/CT tumor markers outperform MRI-based markers for the prediction of lymph node metastases in primary endometrial cancer. European Radiology, 2020, 30, 2443-2453.	4.5	15
31	Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma. British Journal of Cancer, 2020, 122, 1014-1022.	6.4	9
32	High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer. Gynecologic Oncology, 2020, 157, 260-267.	1.4	32
33	Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models. Cancers, 2020, 12, 370.	3.7	10
34	Plasma growth differentiation factor-15 is an independent marker for aggressive disease in endometrial cancer. PLoS ONE, 2019, 14, e0210585.	2.5	7
35	Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study. Human Pathology, 2019, 89, 90-98.	2.0	5
36	Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC. Cancer & Metabolism, 2019, 7, 6.	5.0	51

#	Article	IF	Citations
37	Impact of body mass index and fat distribution on sex steroid levels in endometrial carcinoma: a retrospective study. BMC Cancer, 2019, 19, 547.	2.6	14
38	Poor outcome in hypoxic endometrial carcinoma is related to vascular density. British Journal of Cancer, 2019, 120, 1037-1044.	6.4	10
39	Blood Metabolites Associate with Prognosis in Endometrial Cancer. Metabolites, 2019, 9, 302.	2.9	12
40	Imaging of Preclinical Endometrial Cancer Models for Monitoring Tumor Progression and Response to Targeted Therapy. Cancers, 2019, 11, 1885.	3.7	5
41	PIK3CA Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma. Clinical Cancer Research, 2019, 25, 334-345.	7.0	17
42	Blood steroids are associated with prognosis and fat distribution in endometrial cancer. Gynecologic Oncology, 2019, 152, 46-52.	1.4	13
43	Abstract 4879: Poor outcome in hypoxic endometrial carcinoma is related to vascular density. , 2019, , .		0
44	Genetic overlap between endometriosis and endometrial cancer: evidence from crossâ€disease genetic correlation and GWAS metaâ€analyses. Cancer Medicine, 2018, 7, 1978-1987.	2.8	62
45	InÂvivo MR spectroscopy predicts high tumor grade in endometrial cancer. Acta Radiologica, 2018, 59, 497-505.	1.1	7
46	HER2 expression patterns in paired primary and metastatic endometrial cancer lesions. British Journal of Cancer, 2018, 118, 378-387.	6.4	43
47	Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions. Gynecologic Oncology, 2018, 148, 197-203.	1.4	18
48	Preoperative quantitative dynamic contrast-enhanced MRI and diffusion-weighted imaging predict aggressive disease in endometrial cancer. Acta Radiologica, 2018, 59, 1010-1017.	1.1	33
49	Blocking 17Î²â€hydroxysteroid dehydrogenase type 1 in endometrial cancer: a potential novel endocrine therapeutic approach. Journal of Pathology, 2018, 244, 203-214.	4.5	21
50	The prognostic value of preoperative FDG-PET/CT metabolic parameters in cervical cancer patients. European Journal of Hybrid Imaging, 2018, 2, .	1.5	10
51	Class I Phosphoinositide 3-Kinase PIK3CA/p110Î± and PIK3CB/p110Î² Isoforms in Endometrial Cancer. International Journal of Molecular Sciences, 2018, 19, 3931.	4.1	26
52	Identification of highly connected and differentially expressed gene subnetworks in metastasizing endometrial cancer. PLoS ONE, 2018, 13, e0206665.	2.5	11
53	Development of an Image-Guided Orthotopic Xenograft Mouse Model of Endometrial Cancer with Controllable Estrogen Exposure. International Journal of Molecular Sciences, 2018, 19, 2547.	4.1	9
54	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLoS ONE, 2018, 13, e0197561.	2.5	9

#	Article	IF	Citations
55	Asparaginaseâ€like protein 1 expression in curettage independently predicts lymph node metastasis in endometrial carcinoma: a multicentre study. BJOG: an International Journal of Obstetrics and Gynaecology, 2018, 125, 1695-1703.	2.3	9
56	Identification of nine new susceptibility loci for endometrial cancer. Nature Communications, 2018, 9, 3166.	12.8	178
57	Patient-Derived Xenograft Models for Endometrial Cancer Research. International Journal of Molecular Sciences, 2018, 19, 2431.	4.1	32
58	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. International Journal of Molecular Sciences, 2018, 19, 2473.	4.1	3
59	Preoperative tumor texture analysis on MRI predicts highâ€risk disease and reduced survival in endometrial cancer. Journal of Magnetic Resonance Imaging, 2018, 48, 1637-1647.	3.4	91
60	Abstract 1809: Expression of genes in the nuclear receptor superfamily defines a set of prognostic biomarkers in endometrial cancer. , 2018, , .		0
61	High mRNA levels of 17Î²-hydroxysteroid dehydrogenase type 1 correlate with poor prognosis in endometrial cancer. Molecular and Cellular Endocrinology, 2017, 442, 51-57.	3.2	27
62	Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions. Gynecologic Oncology, 2017, 147, 672-677.	1.4	14
63	Type of vascular invasion in association with progress of endometrial cancer. Apmis, 2017, 125, 1084-1091.	2.0	5
64	PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer. Scientific Reports, 2017, 7, 10240.	3.3	19
65	Expression of L1CAM in curettage or high L1CAM level in preoperative blood samples predicts lymph node metastases and poor outcome in endometrial cancer patients. British Journal of Cancer, 2017, 117, 840-847.	6.4	26
66	Clinicopathologic and molecular markers in cervical carcinoma: a prospective cohort study. American Journal of Obstetrics and Gynecology, 2017, 217, 432.e1-432.e17.	1.3	38
67	Endometrial cancer cells exhibit high expression of p110Î² and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation. Oncotarget, 2017, 8, 3881-3894.	1.8	15
68	Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival. Oncotarget, 2017, 8, 9696-9707.	1.8	4
69	Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers. Oncotarget, 2017, 8, 68530-68541.	1.8	7
70	High visceral fat percentage is associated with poor outcome in endometrial cancer. Oncotarget, 2017, 8, 105184-105195.	1.8	33
71	Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients. Oncotarget, 2017, 8, 106989-107001.	1.8	9
72	Tumour-microenvironmental blood flow determines a metabolomic signature identifying lysophospholipids and resolvin D as biomarkers in endometrial cancer patients. Oncotarget, 2017, 8, 109018-109026.	1.8	12

#	Article	IF	Citations
73	The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nature Genetics, 2016, 48, 848-855.	21.4	174
74	Evidence of a genetic link between endometriosis and ovarian cancer. Fertility and Sterility, 2016, 105, 35-43.e10.	1.0	37
75	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	1.4	18
76	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 2016, 7, 69097-69110.	1.8	5
77	Androgen receptor as potential therapeutic target in metastatic endometrial cancer. Oncotarget, 2016, 7, 49289-49298.	1.8	53
78	Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer. Oncotarget, 2016, 7, 69844-69856.	1.8	30
79	Annexinâ€A2 as predictor biomarker of recurrent disease in endometrial cancer. International Journal of Cancer, 2015, 136, 1863-1873.	5.1	39
80	Epithelialâ€Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genetic Epidemiology, 2015, 39, 689-697.	1.3	22
81	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. PLoS ONE, 2015, 10, e0128106.	2.5	44
82	Multimodal Imaging of Orthotopic Mouse Model of Endometrial Carcinoma. PLoS ONE, 2015, 10, e0135220.	2.5	33
83	ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma. Oncotarget, 2015, 6, 28440-28452.	1.8	37
84	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. Human Molecular Genetics, 2015, 24, 3595-3607.	2.9	40
85	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	21.4	221
86	Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1574-1584.	2.5	28
87	Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma. Gynecologic Oncology, 2015, 137, 529-537.	1.4	24
88	PTEN loss is a contextâ€dependent outcome determinant in obese and nonâ€obese endometrioid endometrial cancer patients. Molecular Oncology, 2015, 9, 1694-1703.	4.6	47
89	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecologic Oncology, 2015, 136, 542-548.	1.4	15
90	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications, 2015, 6, 8234.	12.8	63

#	Article	IF	Citations
91	Common variants at theCHEK2gene locus and risk of epithelial ovarian cancer. Carcinogenesis, 2015, 36, 1341-1353.	2.8	24
92	Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. Oncotarget, 2015, 6, 1327-1339.	1.8	50
93	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). Journal of Genetics and Genome Research, 2015, 2, .	0.3	25
94	Abstract LB-120: HER2 as a potential predictive marker and target for therapy in cervical cancer. , 2015, , .		0
95	Stathmin Protein Level, a Potential Predictive Marker for Taxane Treatment Response in Endometrial Cancer. PLoS ONE, 2014, 9, e90141.	2.5	34
96	Introduction of Aromatic Ring-Containing Substituents in Cyclic Nucleotides Is Associated with Inhibition of Toxin Uptake by the Hepatocyte Transporters OATP 1B1 and 1B3. PLoS ONE, 2014, 9, e94926.	2.5	8
97	Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer. Molecular Cancer, 2014, 13, 223.	19.2	88
98	Risk of Ovarian Cancer and the NF-Î^oB Pathway: Genetic Association with IL1A and TNFSF10. Cancer Research, 2014, 74, 852-861.	0.9	48
99	Landscape of genomic alterations in cervical carcinomas. Nature, 2014, 506, 371-375.	27.8	708
100	Molecular profiling in fresh tissue with high tumor cell content promotes enrichment for aggressive adenocarcinomas in cervix. Pathology Research and Practice, 2014, 210, 774-778.	2.3	0
101	Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions. European Journal of Cancer, 2014, 50, 3003-3010.	2.8	73
102	Consortium analysis of gene and geneâ€“folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. Molecular Nutrition and Food Research, 2014, 58, 2023-2035.	3.3	16
103	Switch in FOXA1 Status Associates with Endometrial Cancer Progression. PLoS ONE, 2014, 9, e98069.	2.5	22
104	Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene. Oncotarget, 2014, 5, 1052-1061.	1.8	35
105	Abstract 2875: ATAD2 overexpression indentifies aggressive endometrial carcinomas. , 2014, , .		0
106	Abstract 4692: Relationships between somatic genomic alterations, tumor stage and progression-free survival in cervical cancer. , 2014, , .		0
107	Abstract 4731: High level of nuclear heat-shock factor 1 is associated with aggressive disease and suggests targets for therapy in endometrial carcinoma. , 2014, , .		0
108	Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. European Journal of Cancer, 2013, 49, 3431-3441.	2.8	123

#	Article	IF	Citations
109	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics, 2013, 45, 362-370.	21.4	326
110	Off-target effect of the Epac agonist 8-pCPT-2â€²-O-Me-cAMP on P2Y12 receptors in blood platelets. Biochemical and Biophysical Research Communications, 2013, 437, 603-608.	2.1	15
111	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	21.4	493
112	Lack of Estrogen Receptor-Î± Is Associated with Epithelialâ€“Mesenchymal Transition and PI3K Alterations in Endometrial Carcinoma. Clinical Cancer Research, 2013, 19, 1094-1105.	7.0	120
113	ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas. Modern Pathology, 2013, 26, 428-434.	5.5	61
114	Polymorphisms in Inflammation Pathway Genes and Endometrial Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 216-223.	2.5	22
115	High Phospho-Stathmin(Serine38) Expression Identifies Aggressive Endometrial Cancer and Suggests an Association with PI3K Inhibition. Clinical Cancer Research, 2013, 19, 2331-2341.	7.0	35
116	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nature Communications, 2013, 4, 1628.	12.8	144
117	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nature Communications, 2013, 4, 1627.	12.8	98
118	Integrated Genomic Analysis of the 8q24 Amplification in Endometrial Cancers Identifies ATAD2 as Essential to MYC-Dependent Cancers. PLoS ONE, 2013, 8, e54873.	2.5	70
119	PI3K Pathway in Gynecologic Malignancies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e218-e221.	3.8	14
120	Abstract 4604: Landscape of human and viral genomic alterations in cervical carcinomas.. , 2013, , .		0
121	Loss of GPER identifies new targets for therapy among a subgroup of ERÎ±-positive endometrial cancer patients with poor outcome. British Journal of Cancer, 2012, 106, 1682-1688.	6.4	54
122	Genome-Wide Association Study Identifies a Possible Susceptibility Locus for Endometrial Cancer. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 980-987.	2.5	32
123	Stratification based on high tumour cell content in fresh frozen tissue promotes selection of aggressive endometrial carcinomas. Histopathology, 2012, 60, 516-519.	2.9	5
124	High-Throughput Mutation Profiling of Primary and Metastatic Endometrial Cancers Identifies KRAS, FGFR2 and PIK3CA to Be Frequently Mutated. PLoS ONE, 2012, 7, e52795.	2.5	34
125	Nostocyclopeptide-M1: A Potent, Nontoxic Inhibitor of the Hepatocyte Drug Transporters OATP1B3 and OATP1B1. Molecular Pharmaceutics, 2011, 8, 360-367.	4.6	29
126	The cAMP-Dependent Protein Kinase Pathway as Therapeutic Target â€“ Possibilities and Pitfalls. Current Topics in Medicinal Chemistry, 2011, 11, 1393-1405.	2.1	18

#	Article	IF	Citations
127	Abstract 4169: Loss of GPR30 expression identifies estrogen receptor positive endometrial carcinoma patients with poor outcome. , 2011, , .		0
128	Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Molecular Cancer, 2010, 9, 135.	19.2	247
129	Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death. Blood, 2008, 111, 2866-2877.	1.4	35
130	Serine/Threonine Protein Phosphatases in Apoptosis. , 2006, , 151-166.		2
131	cAMP protects neutrophils against TNF-Î±-induced apoptosis by activation of cAMP-dependent protein kinase, independently of exchange protein directly activated by cAMP (Epac). Journal of Leukocyte Biology, 2004, 76, 641-647.	3.3	41
132	Mitochondrial-Targeted Fatty Acid Analog Induces Apoptosis with Selective Loss of Mitochondrial Glutathione in Promyelocytic Leukemia Cells. Chemistry and Biology, 2003, 10, 609-618.	6.0	20
133	cAMP effector mechanisms. Novel twists for an â€˜oldâ€™ signaling system. FEBS Letters, 2003, 546, 121-126.	2.8	174
134	Ca2+/Calmodulin-dependent Protein Kinase II Is Required for Microcystin-induced Apoptosis. Journal of Biological Chemistry, 2002, 277, 2804-2811.	3.4	106